Dongmei Zhao

Dongmei Zhao


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 September 2020 in Oxidative Medicine and Cellular Longevity
Verified
Journal Article
Open access
PDF file
YWYueming Wang
Yueming Wang
NZNannan Zhao
Nannan Zhao
YXYanlei Xiong
Yanlei Xiong
JZJiashen Zhang
Jiashen Zhang
DZDongmei Zhao
Dongmei Zhao
YXYanlian Xiong
Yanlian Xiong
Red blood cells (RBCs) are susceptible to sustained free radical damage during circulation, while the changes of antioxidant capacity and regulatory mechanism of RBCs under different oxygen gradients remain unclear. Here, we investigated the changes of oxidative damage and antioxidant capacity of RBCs in different oxygen gradients and identified the underlying mechanisms using an in vitro model of the hypoxanthine/xanthine oxidase (HX/XO) system. In the present study, we reported that the hypoxic RBCs showed much higher oxidative stress injury and lower antioxidant capacity compared with normoxic RBCs. In addition, we found that the disturbance of the recycling process, but not de novo synthesis of glutathione (GSH), accounted for the significantly decreased antioxidant capacity of hypoxic RBCs compared to normoxic RBCs. We further elucidated the underlying molecular mechanism by which oxidative phosphorylation of Band 3 blocked the hexose monophosphate pathway (HMP) and decreased NADPH production aggravating the dysfunction of GSH synthesis in hypoxic RBCs under oxidative conditions.

19 September 2019 in Biomolecules
Verified
Journal Article
Open access
PDF file
MLMinjing Li
Minjing Li
SHShiyu Hao
Shiyu Hao
LCLi chunling
Li chunling
HXHuimin Xiao
Huimin Xiao
LSLiyuan Sun
Liyuan Sun
YYYancun Yin
Yancun Yin
Current strategies are not especially successful in the treatment of acute myeloid leukemia (AML). The identification and characterization of oncogenes crucial to the survival and growth of leukemia cells will provide potential targets for the exploitation of novel therapies. Herein, we report that the elevated expression of SH3 domain-binding protein 5 (SH3BP5) significantly correlates with poor outcomes of AML patients. To test whether SH3BP5 contributes to the growth and survival of AML cells, we use the shRNA-encoding lentivirus system to achieve the knockdown of SH3BP5 expression in human AML cell lines U937, THP-1, Kasumi-1, and MV4-11. Functionally, the knockdown of SH3BP5 expression markedly inhibits the cell viability and induced apoptosis of these leukemia cells. Mechanistically, western blot analysis indicates that the knockdown of SH3BP5 expression decreases the phosphorylation of JNK and BAD. Moreover, the JNK agonist anisomycin rescues the growth inhibition phenotype of SH3BP5 deficiency in THP-1 cells. Moreover, the expression of SH3BP5 positively correlates with CD25 and CD123 levels. Finally, our study highlights the crucial role of SH3BP5 in promoting the survival of AML cells, and its suppression may be a potential therapeutic strategy for treating human AML.

10 December 2022 in Progress in Biomaterials
Verified
Journal Article
Closed access
PDF file
LMLina Ma
Lina Ma
LFLi Fu
Li Fu
CGChengxu Gu
Chengxu Gu
HWHaonan Wang
Haonan Wang
ZYZhenghai Yu
Zhenghai Yu
NZNaiLi Zhang
NaiLi Zhang

1 January 2022
Verified
Journal Article
Closed access
LMLiying Ma
Liying Ma
XXXiao-Ting Xu
Xiao-Ting Xu
QDQian Dou
Qian Dou
DZDongmei Zhao
Dongmei Zhao
YXYun-Gai Xiang
Yun-Gai Xiang
LTLi Tan
Li Tan